Free tool
FAERS Monitor: Likmez
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216755 or its brand name (Likmez, Metronidazole). Reports on generic versions are filed under their own applications.
Reports
23
Serious
18
78% of reports
Hospitalization
18
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- toxic encephalopathy4
- balance disorder2
- diplopia2
- drug ineffective2
- encephalopathy2
- posterior reversible encephalopathy syndrome2
- product taste abnormal2
- septic shock2
- vomiting2
- ataxia1
- bipolar i disorder1
- bowel movement irregularity1
- central vision loss1
- cerebellar ataxia1
- disseminated intravascular coagulation1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 1 |
| 2024 | 12 |
| 2025 | 4 |
| 2026 | 6 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,136 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| central vision loss | 1 | 4123.4 | 603.7 | 1,025 |
| cerebellar ataxia | 1 | 956.5 | 140.5 | 238 |
| toxic encephalopathySignal | 4 | 722.6 | 296.4 | 2,205 |
| bipolar i disorder | 1 | 417.0 | 61.3 | 103 |
| posterior reversible encephalopathy syndrome | 2 | 191.6 | 51.0 | 213 |
| product taste abnormal | 2 | 135.1 | 35.9 | 149 |
| bowel movement irregularity | 1 | 119.4 | 17.6 | 29 |
| ataxia | 1 | 77.1 | 11.3 | 18 |
| encephalopathy | 2 | 74.5 | 19.8 | 81 |
| diplopia | 2 | 70.4 | 18.7 | 76 |
| disseminated intravascular coagulation | 1 | 65.0 | 9.6 | 15 |
| septic shock | 2 | 42.0 | 11.2 | 44 |
| balance disorder | 2 | 21.2 | 5.6 | 21 |
| vomiting | 2 | 3.9 | 1.0 | 2 |
| drug ineffective | 2 | 1.4 | 0.4 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.